9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors

Inclusion criteria

• Competent to comprehend, sign, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved informed consent form.
• Female subjects aged 18 to 75 years (including 18 and 75 years).
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Histopathological diagnosed of advanced gynecological tumors.
• Subjects must submit tumor tissues for test.
• Life expectancy of ≥ 12 weeks.
• Subjects must have measurable disease according to RECIST (version 1.1).
• Adequate organ functions.
• Sexually active fertile subjects must agree to use methods of contraception during the study and at least 180 days after termination of study therapy.
• Subjects are willing to follow study procedures.

Exclusion criteria

• History of another malignancy within 3 years before the first dose of study drug.
• Patients with ongoing clinically significant toxicities related to prior treatment.
• Presence of Grade ≥ 2 peripheral neuropathy.
• Exclusion of prior diseases and prior treatments as specified in the protocol.
• Comorbidities: a. Hemoglobin A1C ≥ 8%; b. Ocular diseases or symptoms present prior to the first dose of study medication; c. Severe respiratory diseases; d. Clinically significant cardiovascular or cerebrovascular diseases within 6 months prior to the first dose of study medication; e. Active autoimmune diseases within 2 years prior to the first dose of study medication, or a history of autoimmune diseases with potential for recurrence; f. Active infections; g. Severe arterial or venous thromboembolic events.
• Clinically significant bleeding symptoms or a clear bleeding tendency within 3 months prior to the first dose of medication.
• Subjects with central nervous system (CNS) metastases and/or carcinomatous meningitis.
• Pleural, peritoneal, or pericardial effusion with clinical symptoms or requiring repeated drainage procedures.
• Prior Treatments: a. Major surgical procedures within 28 days prior to the first dose of study medication; b. Administration of other investigational drugs or experimental medical devices within 28 days prior to the first dose of study medication; c. Use of P-glycoprotein inhibitors or inducers, or potent CYP3A4 inhibitors within 14 days prior to the first dose of study medication; d. Receipt of live vaccines within 28 days prior to the first dose of study medication or planned administration of any live vaccine during the study period; e. Prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation;.
• Subjects with a history of drug abuse or psychiatric disorders, or suspected allergy, intolerance, or severe infusion reactions to the investigational drug or any of its components.
• Pregnant or lactating women.
• Not suitable to receive study treatment for other conditions as per investigator.